ARTELO BIOSCIENCES ARTL 深 沪
已收盘 08-22 16:00:00 美东时间
9.35
-0.180
-1.89%
华盛通- 最 高9.66
- 今 开9.455
- 成交量 2.37万股
- 最 低 9.25
- 昨 收 9.53
- 总市值 511.26万
- 52周最高 28.60
- 市盈率 静 --
- 换手率 4.34%
- 52周最低 4.9176
- 委 比 -31.41%
- 总股本 54.68万
- 历史最高 450.00
- 量 比 2.16
- 振 幅 4.30%
- 历史最低 4.9176
- 每 手 1
- 风险率 0.13%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results
Artelo Biosciences provided a business update for Q2 2025, highlighting clinical progress across its pipeline: - ART26.12: Phase 1 SAD study completed with positive safety results; MAD study planned for Q4 2025. Data presented at the British Pain Society Conference supports its potential for osteoarthritis and mood disorders. - ART27.13: Phase 2 CAReS study in cancer anorexia-cachexia syndrome expected to report data in Q3 2025; safety demonstra...
08-13 12:00
Artelo Biosciences Secures European Patent For ART27.13 Commercial Formulation, Extending Protection Through 2041; Phase 2 Trial Advances For Cancer-Related Anorexia Treatment
Extends Patent Protection Through December 2041ART27.13 is Currently under Evaluation in a Phase 2 Study for the Treatment of Cancer-Related AnorexiaSOLANA BEACH, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Artelo
08-11 21:17
Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13
Artelo Biosciences, Inc. announced that the European Patent Office has granted a Notice of Allowance for its patent application related to the commercial formulation of ART27.13, a cannabinoid agonist for cancer-related anorexia. The allowed claims protect compositions of ART27.13 in polyethylene glycol, extending patent protection through December 2041. This achievement strengthens the commercial potential of ART27.13, which is currently under e...
08-11 13:15
美股大行评级 | 潜在涨幅123.33%！Maxim Group上调优利系统目标价至9美元，评级升至"买入"
今日重点评级关注：Maxim Group：上调优利系统评级至"买入"，目标价9美元；Canaccord Genuity：维持Enovix"买入"评级，目标价从20美元升至22美元
08-05 08:35
Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset
Artelo Biosciences entered into a PIPE for $9.475 million to support its SOL treasury strategy, becoming the first publicly traded pharma company to adopt SOL as a reserve asset. Lead investor Bartosz Lipiński will serve as a technical partner through CUBE, which secures storage and staking for Artelo's digital assets. The company aims to leverage Solana's scalability and decentralized infrastructure for long-term growth and enhanced shareholder ...
08-04 11:30
Artelo Biosciences shares are trading higher after the company received written scientific advice from the UK MHRA affirming the proposed design for its Phase 1 trial of ART12.11.
Artelo Biosciences shares are trading higher after the company received written...
08-01 19:51
Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company’s Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression
Artelo Biosciences received positive scientific advice from the UK's MHRA on ART12.11, a novel CBD and TMP cocrystal, supporting its streamlined development plan. MHRA agreed ART12.11 may qualify for ILAP, potentially accelerating its path to market. ART12.11 has shown promising results in preclinical studies, with superior efficacy compared to CBD alone. Artelo plans to pursue ILAP and initiate clinical trials early next year, aiming to address ...
08-01 11:45
Artelo Biosciences Announces At-The-Market Offering Agreement
The latest update is out from Artelo Biosciences ( ($ARTL) ). On July 18, 2025,...
07-19 04:57
